Roche's Genentech has announced new long-term data for Vabysmo, showing sustained improvements in retinal drying and vision for patients with Retinal Vein Occlusion (RVO). The data indicates that up to 60% of patients could extend treatment intervals to three or four months. Detailed results from two global Phase III RVO studies will be presented at the Angiogenesis, Exudation, and Degeneration 2024 conference. Vabysmo is approved in the U.S. for RVO and in over 90 countries for wet AMD and DME.